121 related articles for article (PubMed ID: 2537335)
1. Bromocriptine-responsive Cushing's disease associated with anterior pituitary corticotroph hyperplasia or normal pituitary gland.
Croughs RJ; Koppeschaar HP; van't Verlaat JW; McNicol AM
J Clin Endocrinol Metab; 1989 Feb; 68(2):495-8. PubMed ID: 2537335
[TBL] [Abstract][Full Text] [Related]
2. Biochemical assessment of Cushing's disease in patients with corticotroph macroadenomas.
Katznelson L; Bogan JS; Trob JR; Schoenfeld DA; Hedley-Whyte ET; Hsu DW; Zervas NT; Swearingen B; Sleeper M; Klibanski A
J Clin Endocrinol Metab; 1998 May; 83(5):1619-23. PubMed ID: 9589666
[TBL] [Abstract][Full Text] [Related]
3. Remission of pituitary-dependent Cushing's disease after removal of nonneoplastyic pituitary gland.
Taylor HC; Velasco ME; Brodkey JS
Arch Intern Med; 1980 Oct; 140(10):1366-8. PubMed ID: 6252859
[TBL] [Abstract][Full Text] [Related]
4. Sodium valproate and cyproheptadine may independently induce a remission in the same patient with Cushing's disease.
Koppeschaar HP; Croughs RJ; Thijssen JH; Schwarz F
Acta Endocrinol (Copenh); 1983 Oct; 104(2):160-3. PubMed ID: 6314723
[TBL] [Abstract][Full Text] [Related]
5. Response to neurotransmitter modulating drugs in patients with Cushing's disease.
Koppeschaar HP; Croughs RJ; Thijssen JH; Schwarz F
Clin Endocrinol (Oxf); 1986 Dec; 25(6):661-7. PubMed ID: 3115630
[TBL] [Abstract][Full Text] [Related]
6. Adrenocorticotropin-secreting pituitary adenomas originate from the anterior or the intermediate lobe in Cushing's disease: differences in the regulation of hormone secretion.
Lamberts SW; de Lange SA; Stefanko SZ
J Clin Endocrinol Metab; 1982 Feb; 54(2):286-91. PubMed ID: 6274899
[No Abstract] [Full Text] [Related]
7. [Unique type of Cushing's disease in clinical profile: cyclic Cushing's syndrome and Cushing's disease with favorable outcome to a high daily dose of bromocriptine].
Yasuda K; Miura K
Nihon Naibunpi Gakkai Zasshi; 1994 Jan; 70(1):11-6. PubMed ID: 7958078
[TBL] [Abstract][Full Text] [Related]
8. Six year remission of ACTH-dependent Cushing's syndrome using bromocriptine.
Atkinson AB; Kennedy AL; Sheridan B
Postgrad Med J; 1985 Mar; 61(713):239-42. PubMed ID: 2984649
[TBL] [Abstract][Full Text] [Related]
9. Reduction of pituitary tumor size with clinical and biochemical improvement with bromocriptine in a normoprolactinemic Cushing's disease.
Hayashi H; Mercado-Asis LB; Murayama M; Yamakita N; Yasuda K; Miura K
Endocrinol Jpn; 1990 Dec; 37(6):875-82. PubMed ID: 1966282
[TBL] [Abstract][Full Text] [Related]
10. The effect of cyproheptadine and/or bromocriptine on plasma ACTH levels in patients cured of Cushing's disease by bilateral adrenalectomy.
Whitehead HM; Beacom R; Sheridan B; Atkinson AB
Clin Endocrinol (Oxf); 1990 Feb; 32(2):193-201. PubMed ID: 2161298
[TBL] [Abstract][Full Text] [Related]
11. [Clinical remission in Cushing's disease through treatment with sodium valproate and bromocriptine].
García Rojas JF; Mangas Rojas A; Barba Chacón A; García Osle M; Zamora Madaria E
Rev Clin Esp; 1991 Jan; 188(1):37-40. PubMed ID: 2063025
[TBL] [Abstract][Full Text] [Related]
12. Cyclic Cushing's disease in long-term remission with a daily low dose of bromocriptine.
Adachi M; Takayanagi R; Yanase T; Sakai Y; Ikuyama S; Nakagaki H; Osamura Y; Sanno N; Nawata H
Intern Med; 1996 Mar; 35(3):207-11. PubMed ID: 8785455
[TBL] [Abstract][Full Text] [Related]
13. Pituitary Cushing's disease without adenoma.
Schnall AM; Kovacs K; Brodkey JS; Pearson OH
Acta Endocrinol (Copenh); 1980 Jul; 94(3):297-303. PubMed ID: 6252743
[TBL] [Abstract][Full Text] [Related]
14. Absence of Cushingoid phenotype in a patient with Cushing's disease due to defective cortisone to cortisol conversion.
Tomlinson JW; Draper N; Mackie J; Johnson AP; Holder G; Wood P; Stewart PM
J Clin Endocrinol Metab; 2002 Jan; 87(1):57-62. PubMed ID: 11788623
[TBL] [Abstract][Full Text] [Related]
15. Long-term quiescence of ectopic Cushing's syndrome caused by pulmonary neuroendocrine tumor (typical carcinoid) and tumorlets: spontaneous remission or therapeutic effect of bromocriptine?
Francia G; Davì MV; Montresor E; Colato C; Ferdeghini M; Lo Cascio V
J Endocrinol Invest; 2006 Apr; 29(4):358-62. PubMed ID: 16699304
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness versus efficacy: the limited value in clinical practice of high dose dexamethasone suppression testing in the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome.
Aron DC; Raff H; Findling JW
J Clin Endocrinol Metab; 1997 Jun; 82(6):1780-5. PubMed ID: 9177382
[TBL] [Abstract][Full Text] [Related]
17. In vivo and in vitro studies in a patient with cyclical Cushing's disease showing some responsiveness to bromocriptine.
Watanobe H; Aoki R; Takebe K; Nakazono M; Kudo M
Horm Res; 1991; 36(5-6):227-34. PubMed ID: 1668381
[TBL] [Abstract][Full Text] [Related]
18. Use of bromocriptine for treatment of Cushing's disease caused by an adenoma originating from the intermediate lobe of the pituitary.
Romer TE; Lastowiecki PM; Klimaszewski J
Endokrynol Pol; 1987; 38(1):97-105. PubMed ID: 3428237
[No Abstract] [Full Text] [Related]
19. Long-term remission rates after pituitary surgery for Cushing's disease: the need for long-term surveillance.
Atkinson AB; Kennedy A; Wiggam MI; McCance DR; Sheridan B
Clin Endocrinol (Oxf); 2005 Nov; 63(5):549-59. PubMed ID: 16268808
[TBL] [Abstract][Full Text] [Related]
20. Responsiveness of the hypophyseal-adrenocortical axis to corticotropin-releasing factor in pituitary-dependent Cushing's disease.
Pieters GF; Hermus AR; Smals AG; Bartelink AK; Benraad TJ; Kloppenborg PW
J Clin Endocrinol Metab; 1983 Sep; 57(3):513-6. PubMed ID: 6308029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
